Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors.
Falagario UG, Lantz A, Jambor I, Busetto GM, Bettocchi C, Finati M, Ricapito A, Luzzago S, Ferro M, Musi G, Totaro A, Racioppi M, Carbonara U, Checcucci E, Manfredi M, D'Aietti D, Porcaro AB, Nordström T, Björnebo L, Oderda M, Soria F, Taimen P, Aronen HJ, Perez IM, Ettala O, Marchioni M, Simone G, Ferriero M, Brassetti A, Napolitano L, Carmignani L, Signorini C, Conti A, Ludovico G, Scarcia M, Trombetta C, Claps F, Traunero F, Montanari E, Boeri L, Maggi M, Del Giudice F, Bove P, Forte V, Ficarra V, Rossanese M, Mucciardi G, Pagliarulo V, Tafuri A, Mirone V, Schips L, Antonelli A, Gontero P, Cormio L, Sciarra A, Porpiglia F, Bassi P, Ditonno P, Boström PJ, Messina E, Panebianco V, De Cobelli O, Carrieri G; PROMOD Study Group. Falagario UG, et al. Among authors: perez im. World J Urol. 2023 Nov;41(11):2967-2974. doi: 10.1007/s00345-023-04634-2. Epub 2023 Oct 3. World J Urol. 2023. PMID: 37787941 Free PMC article.
Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Fossati N, Martini A, Cucchiara V, Picker W, Haug E, Ratnani P, Haines K, Lewis S, Sujit N, Selvaggio O, Sanguedolce F, Macarini L, Cormio L, Nordström T, Tewari A, Briganti A, Boström PJ, Carrieri G. Falagario UG, et al. Among authors: perez im. Eur Urol Oncol. 2021 Dec;4(6):971-979. doi: 10.1016/j.euo.2020.08.014. Epub 2020 Sep 21. Eur Urol Oncol. 2021. PMID: 32972896
Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).
Jambor I, Boström PJ, Taimen P, Syvänen K, Kähkönen E, Kallajoki M, Perez IM, Kauko T, Matomäki J, Ettala O, Merisaari H, Kiviniemi A, Dean PB, Aronen HJ. Jambor I, et al. Among authors: perez im. J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. doi: 10.1002/jmri.25641. Epub 2017 Feb 6. J Magn Reson Imaging. 2017. PMID: 28165653
Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study.
Knaapila J, Jambor I, Perez IM, Ettala O, Taimen P, Verho J, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ. Knaapila J, et al. Among authors: perez im. Eur Urol Oncol. 2020 Oct;3(5):648-656. doi: 10.1016/j.euo.2019.08.008. Epub 2019 Sep 6. Eur Urol Oncol. 2020. PMID: 31501082
Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies.
Knaapila J, Jambor I, Ettala O, Taimen P, Verho J, Perez IM, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ. Knaapila J, et al. Among authors: perez im. Eur Urol Focus. 2021 May;7(3):522-531. doi: 10.1016/j.euf.2020.04.007. Epub 2020 May 14. Eur Urol Focus. 2021. PMID: 32418878
How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database.
Jambor I, Martini A, Falagario UG, Ettala O, Taimen P, Knaapila J, Syvänen KT, Steiner A, Verho J, Perez IM, Merisaari H, Vainio P, Lamminen T, Saunavaara J, Carrieri G, Boström PJ, Aronen HJ. Jambor I, et al. Among authors: perez im. Acta Radiol Open. 2021 Nov 30;10(11):20584601211060707. doi: 10.1177/20584601211060707. eCollection 2021 Nov. Acta Radiol Open. 2021. PMID: 34868663 Free PMC article.
The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
Parekh S, Ratnani P, Falagario U, Lundon D, Kewlani D, Nasri J, Dovey Z, Stroumbakis D, Ranti D, Grauer R, Sobotka S, Pedraza A, Wagaskar V, Mistry L, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Martini A, Picker W, Haug E, Cormio L, Nordström T, Briganti A, Boström PJ, Carrieri G, Haines K, Gorin MA, Wiklund P, Menon M, Tewari A. Parekh S, et al. Among authors: perez im. Eur Urol Open Sci. 2022 May 20;41:45-54. doi: 10.1016/j.euros.2022.04.017. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813258 Free PMC article.
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).
Jambor I, Kuisma A, Kähkönen E, Kemppainen J, Merisaari H, Eskola O, Teuho J, Perez IM, Pesola M, Aronen HJ, Boström PJ, Taimen P, Minn H. Jambor I, et al. Among authors: perez im. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):355-364. doi: 10.1007/s00259-017-3875-1. Epub 2017 Nov 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29147764 Clinical Trial.
24 results